India gets its first indigenous antibiotic: Key things to know

In a major medical breakthrough, Indian scientists have developed Nafithromycin, the nation's first homegrown Macrolide antibiotic, the Ministry of Chemicals and Fertilizers announced on December 6, 2024. This innovative solution tackles antimicrobial resistance, a growing global threat. After 30 years of research, India's pharmaceutical sector has made history, showcasing its capabilities in developing cutting-edge medicines.

All you need to know about the drug

Nafithromycin was officially launched on November 20, 2024, by Union Minister Jitendra Singh. The drug has been developed by Wockhardt with support from the Biotechnology Industry Research Assistance Council (BIRAC) and marketed as MiqnaNafithromycin, marketed as "Miqnaf," targets Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria, which disproportionately affects vulnerable populations such as children, the elderly, and those with compromised immune systems.
The antibiotic is ten times more effective than current other drugs like azithromycin. It offers a three-day treatment regimen, significantly shortening the recovery time while improving patient outcomes.

This drug is designed to treat both typical and atypical drug-resistant bacteria. It comprises superior safety, minimal side effects, and no significant drug interactions.

What is Antimicrobial Resistance (AMR)?

Antimicrobial Resistance (AMR) occurs when microorganisms (bacteria, viruses, fungi, parasites) evolve mechanisms to resist the effects of medicines, making treatments ineffective. This threatens global health, food security and economic stability.

When does it cause?

Here are several points when AMR occurs:

• Overuse and misuse of antibiotics
• Poor infection control practices
• Lack of new antimicrobial development
• Environmental contamination